Japanese pharmaceutical giant Takeda and U.S.-based biotech startup Nabla Bio have announced a significant expansion of their collaboration in the field of AI-driven drug discovery. This new agreement is valued at over $1 billion and represents the second major deal between the two companies.
Nabla Bio will harness its proprietary Joint Atomic Model (JAM) technology in this multi-year partnership. This innovative platform leverages machine learning and deep learning techniques to accelerate the discovery and design of next-generation protein-based therapeutics, aiming to bring novel medicines to patients faster and with greater precision.
This deal underlines growing confidence in the ability of AI tools such as Nabla’s platform to transform the pharmaceutical R&D landscape. By integrating advanced models that predict protein structures and functions, the partnership seeks to improve hit rates and reduce the time and costs associated with traditional drug development.
As AI drug discovery becomes increasingly central to biopharma strategy, collaborations like this are anticipated to become more prevalent. Takeda and Nabla Bio’s expanded agreement marks a notable step towards broader adoption of artificial intelligence in the pursuit of complex, life-saving therapies.
Stay Informed with the Latest news and trends in AI
The Domain has been successfully submitted. We will contact you ASAP.
